Letermovir Completed Phase 2 Trials for HCMV Reactivation or HCMV End-Organ Disease / Cytomegalovirus Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT01063829Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients